此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A MAD Study of TT301/MW189 in Healthy Volunteers

2020年6月2日 更新者:Linda Van Eldik

A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TT301/MW189 Administered Intravenously to Healthy Volunteers

The purpose of this Study is to find out whether an investigational drug is safe and well tolerated. MW189 is being studied as a possible short-term treatment for people with different types of brain injury. MW189 has previously been given to healthy human volunteers as a single dose, and there were no significant problems or bad effects in people who received the Study drug. However, before it can be tested in people with brain injury, it is important to test MW189 in healthy volunteers when given multiple doses.

研究概览

详细说明

This is a phase 1b study. Written informed consent will be obtained from each study participant before any study-specific procedures or assessments are done.

At various time points noted below, pharmacokinetic (PK) blood sampling will be performed on study participants.

Throughout the study the investigator will be assessing adverse events and concomitant medication.

On-Study/On-Interventions Evaluations/procedures: Participants will arrive at the Phase 1 unit after fasting a minimum of 10 hours, for admission into the unit and will undergo procedures:

  • Medical and medication histories
  • Infection screen
  • Body temperature
  • Vital signs (blood pressure and heart rate)
  • Physical examination and weight
  • Neurological exam
  • Safety laboratory tests (blood and urine)
  • Urine pregnancy test (females only)
  • Alcohol screening (Breathalyzer)
  • Urine drug screen
  • Hepatitis B, C and HIV screening
  • Randomize: Only participants who meet eligibility requirements will be randomized into the study.

Day 1 - Dosing: A light breakfast will be given prior to dosing. Participants will have the following tests/procedures performed at various time points during the day following confirmation of eligibility.

  • 8 electrocardiograms (ECG)
  • 8 vital signs (blood pressure and heart rate)
  • 1 body temperature
  • 12 PK Blood draws
  • 2 study drug administrations

Day 2: A light breakfast will be given prior to dosing.

  • 8 ECGs
  • 8 vital signs (blood pressure and heart rate)
  • 1 body temperature
  • 1 PK blood draw
  • 2 study Drug administration

Day 3: Participants will fast for a minimum of 10 hours. Water is allowed. A Light breakfast will be given before dosing

  • 1 safety laboratory tests (blood and urine)
  • 1 ECG
  • 2 vital signs (blood pressure and heart rate)
  • 1 body temperature
  • 1 PK blood draw
  • 1 neurological examination
  • 2 study drug administrations

Day 4: A Light breakfast will be given before dosing

  • 2 vital signs (blood Pressure and heart rate)
  • 1 body temperature
  • 1 PK blood draw
  • 2 study drug administrations

Day 5: A Light breakfast will be given before dosing

  • 1 ECG
  • 2 vital signs (Blood Pressure and heart rate)
  • 1 body temperature
  • 12 PK blood draw
  • 2 study drug administration

Day 6: Participants will fast for a minimum of 10 hours. Water is allowed. A Light breakfast will be given

  • 1 safety laboratory test (blood and urine)
  • 1 vital sign (Blood pressure and heart rate)
  • 1 body temperature
  • 1 neurological examination
  • 2 PK blood draw

Day 7: A light breakfast will be provided

  • 1 vital sign
  • 1 body temperature
  • 1 PK blood draw

Day 8 (Discharge): Participants will fast for a minimum of 10 hours. Water is allowed. A light breakfast will be offered

  • 1 safety laboratory test (blood and urine)
  • 1 ECG
  • 1 vital sign (blood pressure and heart rate)
  • 1 body temperature
  • 1 physical examination including weight
  • 1 neurological examination

    2 Week Follow-up Visit: Participants will fast for a minimum of 10 hours. Water is allowed.

during this visit participants will have the following tests and procedures performed:

  • 1 safety laboratory test (blood and urine)
  • 1 ECG
  • 1 vital sign (blood pressure and heart rate)
  • 1 body temperature

6-8 Week Follow-up Phone Call: Participants will be asked about any adverse events and any medications they may be taking.

研究类型

介入性

注册 (实际的)

35

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke Clinical Research Unit 40 Duke Medicine Circle

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Willingness and capacity to give informed consent
  • Is in good health
  • Weights 50.0 - 120.0 kg
  • Not pregnant
  • Must agree to use birth control for 1 week after the last day of study drug administration
  • Willingness to comply with protocol requirements, including fasting, alcohol and nicotine restrictions, during the study and is available to complete the study
  • Adequate forearm vein access
  • No significant dietary restrictions
  • Must not have donated blood, platelets, or any other blood components 30 days, or plasma 60 days, prior to consenting. Must also agree not to donate blood, platelets, or any other blood components for 8 weeks after the last dose of study drug

Exclusion Criteria:

  • Lactating or is pregnant
  • severe ischemic heart disease or congestive heart failure
  • Heart attack within the previous 2 years;
  • history of stroke or cardiomyopathy;
  • significant liver or kidney disease;
  • diabetes;
  • history of any autoimmune disorder; or a history of chronic infections
  • a history of cancer
  • has received antibiotic treatment or has undergone a surgical procedure within 30 days of Day 1
  • has a history of Hepatitis C, Hepatitis B or tuberculosis (TB)
  • has a history of Human Immunodeficiency Virus (HIV)
  • a history of alcohol or drug use within the twelve months prior to study drug administration
  • has used any immunosuppressants or chronic anti-inflammatory drugs medication including prescription medication, over-the-counter medication, health/herbal supplement or vitamin by any route of administration within 7 days of Day 1
  • has donated blood within 30 days of consenting or has donated plasma within 60 days of consenting
  • has participated in a clinical trial of an immunosuppressive drug within 6 months of Day 1
  • has received an investigational drug, used an investigational device or received an investigational medical procedure within 60 days of Day 1, or concurrent with participation in this study
  • has participated in any observational studies, experimental studies of non-investigational drugs, devices, or medical procedures within 30 days of Day 1, or concurrent with participation in this study
  • has participated in a previous trial with TT301/MW189
  • has a history of unexplained syncope or fainting from the collection of blood; i.e., autonomic dysfunction.
  • Lack of ability to understand verbal and/ or written English
  • had significant trauma or surgical procedure within 1 month prior to Screening.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1 - TT301/MW189
TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
0.075 mg/kg IV twice daily on Days 1 through 5
其他名称:
  • TT301/MW189
实验性的:Cohort 2 -TT301/MW189
TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
0.15 mg/kg IV twice daily on Days 1 through 5
其他名称:
  • TT301/MW189
实验性的:Cohort 3- TT301/MW189
TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
0.25 mg/kg IV twice daily on Days 1 through 5
其他名称:
  • TT301/MW189
实验性的:Cohort 4- TT301/MW189
TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
0.30 mg/kg IV twice daily on Days 1 through 5
其他名称:
  • TT301/MW189
安慰剂比较:Placebo
No drug intervention.
0.9%氯化钠

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serious Adverse Events
大体时间:4 weeks
The number of participants who experienced serious adverse events.
4 weeks
Treatment-Emergent Adverse Events
大体时间:4 weeks
The number of participants who experienced treatment-emergent adverse events (TEAEs). A TEAE is defined as an adverse event that started during the treatment period.
4 weeks

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetics - Cmax
大体时间:5 days
Maximum observed concentration in plasma.
5 days
Pharmacokinetics - Tmax
大体时间:5 days
Time to maximum concentration
5 days
Pharmacokinetics - AUC
大体时间:5 days
Area under the concentration-time curve
5 days
Pharmacokinetics - T1/2
大体时间:5 days
Terminal half-life (T1/2)
5 days
Pharmacokinetics - Kel
大体时间:5 days
Elimination rate constant
5 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Linda J. Van Eldik, PhD、University of Kentucky
  • 首席研究员:Jeffrey T. Guptill, MD, MA,MHS、Duke University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年3月20日

初级完成 (实际的)

2018年6月4日

研究完成 (实际的)

2018年6月4日

研究注册日期

首次提交

2016年10月20日

首先提交符合 QC 标准的

2016年10月21日

首次发布 (估计)

2016年10月24日

研究记录更新

最后更新发布 (实际的)

2020年6月16日

上次提交的符合 QC 标准的更新

2020年6月2日

最后验证

2020年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • TT301/MW189 Phase 1b

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅